A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis

Biotechnology Letters

Volumn 37, Issue 1, 2015, Pages 219-226

  Liu, Yan Qiu ^a,b   Han, Xiao Fei ^c   Liu, Tiegang ^d   Cheng, Meng Chun ^b   Xiao, Hong Bin ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c DALIAN UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Alendronate; Bone marrow mesenchymal stem cells; Bone remodeling; Co culture; Icarrin; Osteoporosis; Parathyroid hormone

Indexed keywords

CELL CULTURE; CELLS; CYTOLOGY; DISEASES; DRUG PRODUCTS; MAMMALS; PHOSPHATASES; STEM CELLS;

ALENDRONATE; BONE MARROW MESENCHYMAL STEM CELLS; BONE REMODELING; CO-CULTURES; ICARRIN; OSTEOPOROSIS; PARATHYROID HORMONES;

BONE;

ALENDRONIC ACID; FLAVONOID; GLUCOSIDE; ICARRIN; PARATHYROID HORMONE; PLANT EXTRACT;

ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BONE REMODELING; CELL LINE; CHEMISTRY; DRUG EFFECTS; EPIMEDIUM; METABOLISM; MOUSE; OSTEOPOROSIS;

ALENDRONATE; ANIMALS; BONE REMODELING; CELL LINE; EPIMEDIUM; FLAVONOIDS; GLUCOSIDES; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; OSTEOPOROSIS; PARATHYROID HORMONE; PLANT EXTRACTS;

EID: 84940461367     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-014-1661-8     Document Type: Article

References (17)

1. Bao JR, Yang JW, Li SF, Zhao W, Zhang Q, Yan Y (2005) Effects of icarrin on ovariectomized rats. Weisheng Yanjiu 34:191–193
2. Baron R (2011) Osteoporosis therapy-dawn of the post-bisphosphonate era. Nat Rev Endocrinol 8:76–78
3. Bian Q, Huang JH, Yang Z, Ning Y, Zhao YJ, Wang YJ, Shen ZY (2011) Effects of active ingredients in three kidney-tonifying Chinese herbal drugs on gene expression profile of bone marrow stromal cells from a rat model of corticosterone-induced osteoporosis. Zhong Xi Yi Jie He Xue Bao 9:179–185
4. Burmeister B, Domaschke H, Gelinsky M, Rösen-Wolff A, Hanke Th et al (2003) Co-culture of osteoblasts and osteoclasts on resorbable mineralised collagen scaffolds: establishment of an in vitro model of bone remodeling. Eur Cells Mater 5(suppl 2):18–19
5. Deal C (2009) Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 5:20–27
6. Fong JE, Cassir N, Nihouannen DL, Komarova SV (2008) The role of osteoclasts in Osteoblast regulation. Eur Cells Mater 16(Suppl 4):22
7. Heinemann C, Heinemann S, Worch H, Hanke T (2011) Development of an osteoblast/osteoclast co-culture derived by human bone marrow stromal cells and human monocytes for biomaterials testing. Eur Cells Mater 21:80–93
8. Huang J, Yuan L, Wang X, Zhang TL, Wang K (2007) Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci 81:832–840
9. Ireland JL, Jimenez-Krassel F, Winn ME, Burns DS, Ireland JJ (2004) Evidence for autocrine or paracrine roles of alpha 2-macroglobulin in regulation of estradiol production by granulose cells and development of dominant follicles. Endocrinology 145:2784–2794
10. Khosia S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055
11. Ma HP, Ming LG, Ge BF, Zhai YK, Song P, Xian CJ, Chen KM (2011) Icarrin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem 112:916–923
12. Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76–81
13. Park EK, Kim MS, Lee SH, Kim KH, Park JY, Kim TH, Lee IS, Woo JT, Jung JC, Shin HI, Choi JY, Kim SY (2004) Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation. Biochem Biophys Res Commun 325:1472–1480
14. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ (2009) Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 105:20764–20769
15. Rosen CJ (2003) The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr 13:25–38
16. Whyte MP, Wenkert D, Clemens KL, McAllister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463
17. Zaidi M, Iqbal J (2012) Double protection for weakened bones. Nature 485:47–48